Le territoire, générateur d’inégalités face aux cancers

Agir efficacement contre les inégalités géographiques face aux cancers implique une meilleure compréhension du processus aboutissant à ces inégalités. Une méthodologie interdisciplinaire, traitant conjointement les multiples dimensions par lesquelles le territoire impacte la santé et retraçant l’évolution pronostique des patients, permettrait de répondre à ce besoin. La cohorte EMS, retraçant la prise en charge de patients atteints de sarcomes (cancers rares) en Rhône-Alpes, a été analysée suivant ces principes méthodologiques. L’analyse de 15 variables géographiques ayant une influence sur la santé a permis de distinguer six types de territoires rhônalpins. Cette typologie a ensuite été croisée avec les données de la cohorte EMS pour étudier les pertes de chances propres à chaque type de territoire. La surmortalité des pôles urbains est liée à l’incidence plus importante des sarcomes, quand celle des quartiers populaires et des espaces ruraux s’expliquent davantage par des pertes de chances de survie au cours de la prise en charge.Cancers inequalities in France are among the highest in developed countries and these gaps seem to be growing in the last decades. Territorial inequalities of cancers are analyzed by mapping, which showed higher mortality rates in the North-East Regions of France. At the local scale, standardized mortality rates are two times higher in some areas in the North as other areas in the South-East. Epidemiological studies, mostly based on multilevel analysis, evidence the impact of physical environment, deprivation or health care access on health outcomes. But to identify contextual effects are not sufficient to understand how cancer inequalities are built and how patient’s life context contributes to this process. As epidemiological approach is splitting contextual effects according to health outcomes, geographical approach may have to explain how these contextual effects lead to cancer inequalities, by using territorial typology to summarize these contextual effects. Comparing health outcomes according to this territorial classification may help to understand territory’s ability to generate health inequalities. Several stages across the cancer continuum are implied in the building of the cancer inequalities. This medical process has to be reconstructed to determine whether mortality inequalities are generated by a higher incidence or a lower survival. Moreover, lower survival may be linked to the worse prognosis of patients at diagnosis or to the lower quality of management according to cancer care facilities. Evolution of patients’ prognosis may be reconstructed, thanks to clinical data, in order to identify the most influent steps during this medical process. As a result, to understand the way geographical inequalities of cancers are building requires a multidisciplinary methodology, considering the territory’s contribution as a whole and using longitudinal clinical data. But to reconstitute this medical process is quite difficult actually because few longitudinal and exhaustive data are available. The EMS cohort represents an opportunity to test and discuss this methodological approach. This cohort includes all sarcoma (rare cancer) patients diagnosed in 2005 and 2006, in the Rhône-Alpes Region, and collects clinical data from the diagnosis to the patient follow-up. For this geographical analysis of the EMS cohort, we used a territorial typology generated thanks to multivariate analysis of 15 geographical variables known for their impact on health. Strong differences are noticed in terms of environment exposures, deprivation and health care access between the six types of territory (metropolitan neighborhoods, working-class neighborhoods, urban districts, residential areas, periurban areas, rural areas). This typology seems to be relevant to study geographical inequalities because it enables to distinguish populations which are not exposed to the same risks through their life context. A logistic regression including stage, age and histological subtype, as clinical factors influencing prognosis, estimates the patients’ prognosis at diagnosis. This prognosis score seems to be quite predictive because only 7% of “good prognosis” patients will be dead five years later, whereas this five years death rate raises to 80% for the worse prognosis patients. Analysis of geographical inequalities for sarcoma patients in the Rhône-Alpes Region shows the diversity of situations leading to inequalities of mortality. Indeed, the higher mortality in three types of territories has to be attributed to three different processes. In the case of the urban hub, this high mortality is linked to the higher incidence of sarcoma, as survival rate for patients of these districts is very close to the regional average. As incidence and prognosis risk in the working-class neighborhoods are quite similar to the regional average, higher mortality is due to the loss of survival odds in the course of treatments, probably because of a less optimal management. Despite the second lower incidence among the six types of territories, the worse prognosis of patients (more late-stage diagnosis) and the loss of survival odds during cancer management explained the high mortality rated in the rural areas. Thanks to the EMS cohort’s analysis, we assess the potential of a multidisciplinary methodology studying the territory’s ability to generate geographical inequalities of cancers. Territorial typology, produced without health outcomes data, may be used for every health studies as a synthetic index of the territory and also evidence strong inequalities of health according to people’s life contexts. As public policies struggle to be successful on this issue, to identify key events in the medical process leading to cancer inequalities may improve the territorialization and the efficiency of these policies. Territories with high risk before diagnosis would be focused on prevention and early diagnosis, whereas those more disadvantage during the management would lean towards cancer care quality, access to hospitals and cancer expertise and patient compliance

Short-Term cost impact of compliance with clinical practice guidelines for initial sarcoma treatment

Background: The impact of compliance to clinical practice guidelines (CPG) on outcomes and/or costs of care has not been completely clarified.Objective: To estimate relationships between medical expenditures and compliance to CPG for initial sarcoma treatment.Research design: Selected cohorts of patients diagnosed with sarcoma in 2005 and 2006, and treated at the University hospital and/or the cancer centre of the Rhône-Alpes region, France (n=90). Main outcome measurements were: patient characteristics, compliance with CPG, health outcomes, and costs. Data were mainly extracted from patient records. The logarithm of treatment costs was modelled using linear and Tobit regressions.Results: Rates of compliance with CPG were 86%, 66%, 88%, 89%, and 95% for initial diagnosis, primary surgical excision, wide surgical excision, chemotherapy, and radiotherapy, respectively. Total average costs reached €24,439, with €1,784, €11,225, €10,360, and €1,016 for diagnosis, surgery (primary and wide surgical excisions), chemotherapy, and radiotherapy, respectively. Compliance of diagnosis with CPG decreased the cost of diagnosis, whereas compliance of primary surgical excision increased the cost of chemotherapy. Compliance of chemotherapy with CPG decreased the cost of radiotherapy.Conclusion: Since chemotherapy is one of the major cost drivers, these results support that compliance with guidelines increases medical care expenditures in short term.Oncology; Sarcoma; Cost; Clinical guidelines; Efficacy; Medical Practices; Government Policy; Regulation; Public Health

Clinicians' adherence versus non adherence to practice guidelines in the management of patients with sarcoma: a cost-effectiveness assessment in two European regions

International audienceABSTRACT: BACKGROUND: Although the management of sarcoma is improving, non adherence to clinical practice guidelines (CPGs) remains high, mainly because of the low incidence of the disease and the variety of histological subtypes. Since little is known about the health economics of sarcoma, we undertook a cost-effectiveness analysis (within the CONnective TIssue CAncer NETwork, CONTICANET) comparing costs and outcomes when clinicians adhered to CPGs and when they did not. METHODS: Patients studied had a histological diagnosis of sarcoma, were older than 15 years, and had been treated in the Rhone-Alpes region of France (in 2005/2006) or in the Veneto region of Italy (in 2007). Data collected retrospectively for the three years after diagnosis were used to determine relapse free survival and health costs (adopting the hospital's perspective and a microcosting approach). All costs were expressed in euros at their 2009 value. A 4% annual discount rate was applied to both costs and effects. The incremental cost-effectiveness ratio (ICER) was expressed as cost per relapse-free year gained when management was compliant with CPGs compared with when it was not. To capture uncertainty surrounding ICER, a probabilistic sensitivity analysis was performed based on a non-parametric bootstrap method. RESULTS: A total of 219 patients were included in the study. Compliance with CPGs was observed for 118 patients (54%). Average total costs reached 23,571 euros when treatment was in accordance with CPGs and 27,313 euros when it was not. In relation to relapse-free survival, compliance with CPGs strictly dominates non compliance, i.e. it is both less costly and more effective. Taking uncertainty into account, the probability that compliance with CPGs still strictly dominates was 75%. CONCLUSIONS: Our findings should encourage physicians to increase their compliance with CPGs and healthcare administrators to invest in the implementation of CPGs in the management of sarcoma

Incidence of Sarcoma Histotypes and Molecular Subtypes in a Prospective Epidemiological Study with Central Pathology Review and Molecular Testing

International audienceBACKGROUND: The exact overall incidence of sarcoma and sarcoma subtypes is not known. The objective of the present population-based study was to determine this incidence in a European region (Rhone-Alpes) of six million inhabitants, based on a central pathological review of the cases. METHODOLOGY/PRINCIPAL FINDINGS: From March 2005 to February 2007, pathology reports and tumor blocks were prospectively collected from the 158 pathologists of the Rhone-Alpes region. All diagnosed or suspected cases of sarcoma were collected, reviewed centrally, examined for molecular alterations and classified according to the 2002 World Health Organization classification. Of the 1287 patients screened during the study period, 748 met the criteria for inclusion in the study. The overall crude and world age-standardized incidence rates were respectively 6.2 and 4.8 per 100,000/year. Incidence rates for soft tissue, visceral and bone sarcomas were respectively 3.6, 2.0 and 0.6 per 100,000. The most frequent histological subtypes were gastrointestinal stromal tumor (18%; 1.1/100,000), unclassified sarcoma (16%; 1/100,000), liposarcoma (15%; 0.9/100,000) and leiomyosarcoma (11%; 0.7/100,000). CONCLUSIONS/SIGNIFICANCE: The observed incidence of sarcomas was higher than expected. This study is the first detailed investigation of the crude incidence of histological and molecular subtypes of sarcomas

Contribution of a cohort study to assess the incidence of rare malignant tumors : application to the study of sarcomas in the Rhône-Alpes region

Les sarcomes sont des tumeurs malignes rares, représentant 1% de tous les cancers mais regroupant un large spectre d’entités histopathologiques distinctes. Du fait de leur rareté et de leur difficulté diagnostique, l’épidémiologie des sarcomes reste mal connue. Nous avons décrit l’incidence et la répartition géographique des sarcomes en région Rhône-Alpes grâce à la constitution d’une cohorte prospective et exhaustive de tous les cas incidents en 2005 et 2006, après relecture centralisée systématique des diagnostics par un pathologiste référent. Nous rapportons : - un taux d’incidence brut de 6,2 cas/100 000/an, supérieur à celui publié dans la littérature et confirmé sur les deux années de recueil de données ; - une répartition géographique et une épidémiologie spécifiques selon les sous-types histologiques ; - des discordances de diagnostic portant sur 45% des cas dont 19% de discordances majeures. Nos résultats sont différents des données publiées portant sur des séries rétrospectives ou incomplètes. Ils contribuent à une meilleure connaissance de l’épidémiologie des sarcomes. Ils permettent de poser des hypothèses étiopathogéniques dans la répartition géographique observée notamment pour les tumeurs stromales gastro intestinales et les liposarcomesSarcoma is a rare malignant tumour accounting for 1% of all cancers but comprising a wide range of distinct histopathological types. Given the rarity of cases and the difficulty of diagnosis, the epidemiology of sarcomas is still unclear. We have examined the incidence and the geographical distribution of sarcomas based on the results of a prospective cohort study of all incident cases diagnosed in 2005 and 2006 in the Rhône-Alpes region and after centralized and systematic review of diagnosis by a referent pathologist. We report: - a crude incidence rate of 6.2 cases/100 000/year confirmed on these two years of data collection, higher than the one published in the literature ; - a geographical distribution and epidemiology characteristic of each different histological sub-type ; - diagnostic discordances in 45% of cases, of which 19% were major discordances. Our findings, which differ from data published in retrospective or incomplete series, contribute to a better knowledge of the epidemiology of sarcoma. They make it possible to formulate etiopathogenic hypotheses regarding the geographical distribution of the disease, especially for gastrointestinal stromal tumours and liposarcoma

Le territoire, générateur d’inégalités face aux cancers. Analyse de la cohorte EMS en Région Rhône-Alpes

International audienc

Preterm delivery of a first child and subsequent mothers' risk of ischaemic heart disease: a nested case-control study.

Several studies have suggested that preterm delivery is related to a risk of subsequent ischaemic heart disease (IHD) in the mother. We conducted a nested case-control study in the E3N cohort to assess the association between preterm delivery of a first child and IHD, and the effect of major cardiovascular risk factors on this association. The study included 109 cases and 395 controls. Mothers who had preterm delivery were at an increased risk of IHD [multivariate hazard ratio 2.09 (95% confidence interval 1.07-4.09)]. This association was independent of major cardiovascular risk factors

Répondre aux enjeux des cancers rares. Analyse géographique de la cohorte EMS des sarcomes en région Rhône-Alpes

International audienc

Optimisation du parcours de soins dans la prise en charge initiale des cancers épithéliaux ovariens en France

Présenté par Lionel PerrierInternational audienc